A detailed history of Allspring Global Investments Holdings, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 198 shares of SAGE stock, worth $1,134. This represents 0.0% of its overall portfolio holdings.

Number of Shares
198
Previous 48,808 99.59%
Holding current value
$1,134
Previous $530,000 99.81%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$7.02 - $13.08 $341,242 - $635,818
-48,610 Reduced 99.59%
198 $1,000
Q2 2024

Jul 26, 2024

BUY
$10.58 - $17.9 $1,862 - $3,150
176 Added 0.36%
48,808 $530,000
Q1 2024

Apr 18, 2024

SELL
$18.62 - $26.95 $129,520 - $187,464
-6,956 Reduced 12.51%
48,632 $911,000
Q4 2023

Jan 25, 2024

SELL
$17.1 - $22.26 $54,805 - $71,343
-3,205 Reduced 5.45%
55,588 $1.2 Million
Q3 2023

Oct 27, 2023

BUY
$16.75 - $48.98 $984,782 - $2.88 Million
58,793 New
58,793 $1.21 Million
Q2 2023

Jul 18, 2023

BUY
$40.65 - $59.54 $333,330 - $488,228
8,200 Added 8.68%
102,643 $4.83 Million
Q1 2023

Apr 13, 2023

BUY
$37.27 - $46.57 $256,082 - $319,982
6,871 Added 7.85%
94,443 $3.96 Million
Q4 2022

Jan 23, 2023

SELL
$32.2 - $43.61 $320,744 - $434,399
-9,961 Reduced 10.21%
87,572 $3.34 Billion
Q3 2022

Oct 26, 2022

BUY
$32.28 - $43.27 $786,566 - $1.05 Million
24,367 Added 33.3%
97,533 $3.82 Million
Q2 2022

Jul 25, 2022

SELL
$27.52 - $37.99 $34,675 - $47,867
-1,260 Reduced 1.69%
73,166 $2.36 Million
Q1 2022

May 02, 2022

SELL
$30.71 - $45.71 $55,615 - $82,780
-1,811 Reduced 2.38%
74,426 $2.46 Million
Q4 2021

Jan 28, 2022

BUY
$37.06 - $47.11 $2.83 Million - $3.59 Million
76,237 New
76,237 $3.24 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.